{"prompt": "['MC1752', '15', 'Uncontrolled hypertension defined by a SBP > 160 mm Hg and/or DBP >', '100 mm Hg, with or without anti-hypertensive medication(s)', '3.29a History of untreated HIV', 'NOTE: There is no requirement to screen patients for HIV. Patient with history', 'of HIV infection are allowed if on effective HAART therapy and CD4 count', 'more than 250.', '3.29b', 'History of active hepatitis B infection', 'NOTE: There is no requirement to screen patients for hepatitis B', '3.29c History of active hepatitis C infection', 'NOTE: There is no requirement to screen patients for hepatitis C', '3.29d Known diagnosis of any condition (i.e. post-hematopoietic or organ transplant,', 'rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease,', 'etc.) that requires chronic immunosuppressive therapy.', 'NOTE: Usage of non-steroidal anti-inflammatory medications (NSAIDS) for the', 'treatment of osteoarthritis and uric acid synthesis inhibitors for the treatment of', 'gout are permitted. For questions, please consult the study chair.', '3.29e Other concurrent severe and/or uncontrolled concomitant medical conditions', '(e.g. active or uncontrolled infection, uncontrolled diabetes) that could cause', 'unacceptable safety risks or compromise compliance with the protocol', '3.29f Pregnant or breast-feeding women', '3.29g Women of child-bearing potential, who are biologically able to conceive, and not', 'employing two forms of highly effective contraception. Highly effective', 'contraception must be used throughout the trial and up to 8 weeks after the last', 'dose of study drug (e.g. male condom with spermicidal; diaphragm with', 'spermicide; intra-uterine device). Women of child-bearing potential, defined as', 'sexually mature women who have not undergone a hysterectomy or who have not', 'been naturally postmenopausal for at least 12 consecutive months (i.e., who has', 'had menses any time in the preceding 12 consecutive months), must have a', 'negative serum pregnancy test 14 days prior to registration.', '3.29h', 'Fertile males not willing to use contraception, as stated above', '3.29i', 'Patients unwilling or unable to comply with the protocol', '3.29j', 'Receiving any other investigational agent which would be considered as a', 'treatment for the primary neoplasm.', '3.29k', 'Known prior severe hypersensitivity to investigational product or any component', 'in its formulations, including known severe hypersensitivity reactions to', 'monoclonal antibodies (NCI CTCAE v5.0 Grade > 3)', 'Protocol Version Date: 21JUN2018']['MC1752', '16', '4.0', 'Test Schedule', 'Active Monitoring Phase', 'C4-C10', 'End of', '6 Mo after', 'EOS', '<70', 'Screening', '(D43, D57,', 'Treatment', 'registratio', '9 Mo after', '(12 Mo after', 'days', '(28 days', 'D71, D85,', '(30 days', 'n', 'registration', 'registration)', 'Tests and', 'prior', 'prior to', 'C1', 'C2', 'C3', 'D99, D113,', 'after last', '(Clinical', '(Clinical', '(Clinical', 'procedures', 'to reg', 'reg)', '(D1)', '(D15)', '(D29)', 'D127)', 'dose)', 'Follow-up)', 'Follow-up)', 'Follow-up)', 'Window', '3 days', '3 days', '3 days', '3 days', '14 days', '14 days', '14 days', 'Maximal', 'TURBT/EU', 'X', 'A', 'History and', 'Physical', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Exam', 'Vital Signs,', 'Weight and', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'ECOG PS', 'Height', 'X', 'Pregnancy test', 'X\u00b9', '(serum)', 'Pregnancy test', 'X', 'X', 'X', '(urine) 1', 'Adverse event', 'assessment/', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Toxicity', 'notation4', 'Conmeds', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Disease', 'assessment:', 'CT/MRI', 'X', 'X\u00b3', 'X', 'X', 'X', 'abdomen/', 'pelvis', '8', 'Chest CT8', 'X', 'X3', 'X', 'X', 'X', 'ECG R', 'X', 'Hematology\u00b2', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Protocol Version Date: 21JUN2018']\n\n###\n\n", "completion": "END"}